Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
Hand-out
Press Releases
Duality Biologics  
December 4, 2024

Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics,

avatar profile Olean Times Herald

Olean Times Herald


Local & Social